Future Perspectives: Key Trends Shaping the Ankylosing Spondylitis Market Until 2030

The ankylosing spondylitis market is on a strong growth trajectory, driven by advancements in treatment options and increasing awareness of the disease. With ongoing innovations and expanding therapeutic choices, this market is expected to make significant progress over the next decade. Here, we explore the market size forecasts, key players, emerging trends, and segment-wise breakdown that define the future of ankylosing spondylitis care.

Projected Expansion of the Ankylosing Spondylitis Market by 2030
The ankylosing spondylitis market size is anticipated to reach $9.42 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.3%. This robust growth is primarily fueled by the rising acceptance of biologics and biosimilars, an increased focus on personalized medicine approaches, a broadening pipeline of advanced biologic therapies, and the growing emphasis on long-term disease management. Additionally, significant investments in autoimmune disorder research are playing a crucial role in accelerating market expansion. Key trends shaping this market include the wider adoption of biologic treatments, increased utilization of targeted disease-modifying antirheumatic drugs (DMARDs), greater attention to early diagnosis, the growth of individualized treatment strategies, and enhanced incorporation of physical therapy programs.

Download a free sample of the ankylosing spondylitis market report:
https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Major Companies Steering Growth in the Ankylosing Spondylitis Market
Several leading pharmaceutical and biotech firms dominate the ankylosing spondylitis market, including Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., Janssen Biotech Inc., and Reliance Life Sciences Pvt. Ltd.

Strategic Partnerships Enhancing Treatment Accessibility
In July 2023, Superior Biologics, Inc., a specialty pharmacy and home infusion service provider based in the US, partnered with Coherus BioSciences, Inc. to establish a nationwide distribution agreement. This collaboration aims to expand access to YUSIMRY, a biosimilar version of Humira, which offers patients effective and affordable treatment options for ankylosing spondylitis, rheumatoid arthritis, and Crohn's disease. This partnership also supports employers by significantly reducing specialty drug costs-by more than 85%. Coherus BioSciences is recognized for providing YUSIMRY (adalimumab-aqvh), a biosimilar product specifically designed for ankylosing spondylitis.

The ankylosing spondylitis market is on a strong growth trajectory, driven by advancements in treatment options and increasing awareness of the disease. With ongoing innovations and expanding therapeutic choices, this market is expected to make significant progress over the next decade. Here, we explore the market size forecasts, key players, emerging trends, and segment-wise breakdown that define the future of ankylosing spondylitis care.

Projected Expansion of the Ankylosing Spondylitis Market by 2030
The ankylosing spondylitis market size is anticipated to reach $9.42 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.3%. This robust growth is primarily fueled by the rising acceptance of biologics and biosimilars, an increased focus on personalized medicine approaches, a broadening pipeline of advanced biologic therapies, and the growing emphasis on long-term disease management. Additionally, significant investments in autoimmune disorder research are playing a crucial role in accelerating market expansion. Key trends shaping this market include the wider adoption of biologic treatments, increased utilization of targeted disease-modifying antirheumatic drugs (DMARDs), greater attention to early diagnosis, the growth of individualized treatment strategies, and enhanced incorporation of physical therapy programs.

Download a free sample of the ankylosing spondylitis market report:
https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Major Companies Steering Growth in the Ankylosing Spondylitis Market
Several leading pharmaceutical and biotech firms dominate the ankylosing spondylitis market, including Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., Janssen Biotech Inc., and Reliance Life Sciences Pvt. Ltd.

Strategic Partnerships Enhancing Treatment Accessibility
In July 2023, Superior Biologics, Inc., a specialty pharmacy and home infusion service provider based in the US, partnered with Coherus BioSciences, Inc. to establish a nationwide distribution agreement. This collaboration aims to expand access to YUSIMRY, a biosimilar version of Humira, which offers patients effective and affordable treatment options for ankylosing spondylitis, rheumatoid arthritis, and Crohn's disease. This partnership also supports employers by significantly reducing specialty drug costs-by more than 85%. Coherus BioSciences is recognized for providing YUSIMRY (adalimumab-aqvh), a biosimilar product specifically designed for ankylosing spondylitis.

Emerging Technologies and Innovations Influencing the Ankylosing Spondylitis Market
The ankylosing spondylitis market is witnessing innovation through the development of novel solutions, such as DNA-based wearable hormone patches that enable real-time, non-invasive hormone monitoring. These patches use DNA-derived sensors to detect hormone levels in interstitial fluid, allowing users to track hormonal changes continuously without the need for blood draws. This technology is particularly valuable for fertility tracking and managing overall hormonal health.

For example, in February 2025, Level Zero Health Inc., a biotechnology firm from the UK, successfully raised $6.9 million in an oversubscribed pre-seed funding round to develop the world's first continuous hormone monitoring patch. The DNA-based device measures key hormones including cortisol, progesterone, estrogen, and testosterone via an arm-worn patch, providing real-time feedback that supports fertility monitoring, hormonal health management, and remote clinical supervision. Initially, the company plans to focus on B2B markets such as fertility clinics and endocrine centers, with the potential to expand into consumer wellness sectors.

Detailed Market Segmentation of the Ankylosing Spondylitis Industry
This report categorizes the global ankylosing spondylitis market into various segments for a thorough analysis:

By Treatment Type:
- Painkillers and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
- Biological Therapies
- Steroids
- Physical Therapies
- Surgery

By Molecule Type:
- Biologics
- Biosimilars
- Small Molecules

By Route of Administration:
- Parenteral
- Oral
- Other Routes

By Application:
- Juveniles
- Adults

By End User:
- Hospitals
- Clinics

Further subcategories include:
- Painkillers and NSAIDs divided into over-the-counter and prescription varieties
- DMARDs split into conventional and targeted types
- Biological therapies including TNF inhibitors and IL-17 inhibitors
- Steroids categorized as oral or injectable
- Physical therapy options such as physiotherapy and exercise programs
- Surgical interventions including joint replacement and spinal surgeries

This segmentation helps to provide a clear understanding of the different facets influencing the ankylosing spondylitis market's landscape and growth prospects.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.